Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena).
Tawfik
Hatem A
HA
D000287:Administration, Topical; D004396:Coloring Agents; D003315:Cornea / Q000187:drug effects / Q000473:pathology; D017277:Drug Approval; D015352:Dry Eye Syndromes / Q000175:diagnosis / Q000188:drug therapy*; D015590:Fluorophotometry; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D008086:Lissamine Green Dyes; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000009:adverse effects; D014677:Pharmaceutical Vehicles / Q000008:administration & dosage; D013194:Staining and Labeling / Q000379:methods; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014792:Visual Acuity / Q000502:physiology
D004396:Coloring Agents; D008086:Lissamine Green Dyes; D009883:Ophthalmic Solutions; D014677:Pharmaceutical Vehicles; D006820:Hyaluronic Acid